Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial

By afschroeder • March 3, 2026

Durstenfeld MS, Levkova-Clark M, Ms DL, Schaffer V, Abohashem S, Ma Y, Kawai K, Lu MT, Sereti I, Deeks SG, Tawakol A, Hsue PY. Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial. Am Heart J. 2026 Feb 28:107400. doi: 10.1016/j.ahj.2026.107400. Epub ahead of print. PMID: 41771366.

Tags: arterial inflammation, Cardiology/Epi, Cholesterol, Clinical Trial, Coronary Atherosclerosis, HIV, PCSK9, Publications

Related Posts

Intensive Versus Standard Blood Pressure Control After Endovascular Thrombectomy in Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials

Hashmi TM, Ahmed M, Ashraf H, Shakir M, Bhatti IA, Ahmed F, Alareed A, Hasan A, Ahmed R, Rafiq S, Aized MT, Fonarow GC, Hassan[...]

p21+TREM2+ senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease

Salladay-Perez IA, Avila I, Estrada L, Alexandru AC, Ponce C, Dhingra A, Torres G, Deng CY, Hegde R, Gensheimer J, Kale A, Heckenbach I, Hui[...]

InChagas: Feasibility Study of a Tele-Education Strategy to Promote Early Identification and Care of People Living with Chagas Cardiomyopathy in an Endemic Community in Argentina

Gulayin PE, Gimenez C, Chirino D, Nascimento B, Salvá L, Cavallo AS, Gutierrez L, Blanco L, Flores LPC, Espina E, Shakil SS, Vervoort D, Davis[...]